InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,181.40
(
-0.43%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

linhdtu

Send PM Follow Ignore
Followers 20
Posts 1840
Boards Moderated 0
Alias Born 11/08/2009

linhdtu

Re: DewDiligence post# 157220

Thursday, 02/21/2013 6:16:29 PM

Thursday, February 21, 2013 6:16:29 PM

Post# of 253509
I don’t think Vascepa’s patents will stand up to P-IV challenges
-----------------

What are your reasons for that opinion when actually GSK/Pronova won a patent infringement suit against Par/Teva, whereas Mnta which you so high regarded lost their suit against a Chinese nobody from the LA Inland Empire.

When I looked into Lovaza patent portfolio on the FDA OB site, Lovaza has only 3 patents listed whereas Vascepa has 8 currently listed and counting related to the Anchor trial.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up